Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Growth in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, a growth of 36.1% from the January 31st total of 3,050,000 shares. Approximately 5.2% of the shares of the company are sold short. Based on an average daily volume of 723,400 shares, the days-to-cover ratio is currently 5.7 days.

Analysts Set New Price Targets

A number of research firms recently commented on CNTA. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Trading Down 3.3 %

Shares of Centessa Pharmaceuticals stock opened at $15.04 on Tuesday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -9.83 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09. The firm’s 50-day moving average price is $16.51 and its two-hundred day moving average price is $16.06.

Insider Activity

In related news, insider Karen M. Anderson sold 5,876 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $17.01, for a total transaction of $99,950.76. Following the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $1,216,640.25. This trade represents a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $10,626,702.06. This represents a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 446,682 shares of company stock valued at $7,632,282 over the last ninety days. 11.59% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $162,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.